Featured Clinical Trial:
Advanced ER+ breast cancer after disease progression on a non-steroidal aromatase inhibitor (product/compound: Dasatinib)
ClinicAid Locations: Southern California – Fountain Valley, Corona, Riverside
Status: Enrollment closed.
Condition: Advanced ER+ Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor
Product Name/Compound: Dasatinib
Full Study Title: A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin©) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced ER+ Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor
Study Summary: The purpose of this study is to determine whether exemestane plus dasatinib will be well-tolerated and will increase progression-free survival in the treatment of advanced ER+ breast cancer.
Eligible Participants:
Inclusion (Eligible):
- Invasive estrogen receptor positive breast cancer, locally-advanced or metastatic, with tumor tissue from prior surgery available for analysis
- Prior therapy with a non-steroidal aromatase inhibitor in the adjuvant or advanced setting
- Ability to take oral meds
Exclusion (Not Eligible):
- Pleural or pericardial effusion or ascites
- Any chemotherapy, immunotherapy or antibody therapy for advanced breast cancer
- Any antitumor therapy, including radiotherapy or hormonal therapy, within 15 days prior to study entry
- Prior exposure to exemestane, any Src inhibitor including dasatinib
Study Phase: Phase II (What are Phases?)
To receive information and updates for this trial:
Please contact us and mention the Trial ID below.
Trial ID (ClinicalTrials.gov): NCT00767520
<< Back to all ClinicAid clinical trials
